Literature DB >> 23810745

Severity of emphysema predicts location of lung cancer and 5-y survival of patients with stage I non-small cell lung cancer.

Muath Bishawi1, William Moore, Thomas Bilfinger.   

Abstract

BACKGROUND: Non-small cell lung cancer (NSCLC) has a predilection to occur in emphysematous lungs. The relation between the regional severity of emphysema and the location of NSCLC as well as long-term survival has been poorly studied.
METHODS: Computed tomography (CT) scans of 153 patients with biopsy-proven stage I NSCLC diagnosed between 2001 and 2006 were assigned an emphysema severity score in four regions of the lung. The location of the cancer was compared with the severity of emphysema in that region. Survival was also analyzed.
RESULTS: Thirty-nine patients had no emphysema documented on CT scan and 114 did. The most common location of cancer was the right upper quadrant with 37% of cancers, followed by the left upper quadrant with 23% of cancers. Twenty-two percent of the cancers occurred in the right lower quadrant, and only 12% were in the left lower quadrant. There is a strong association for cancer being located in the area with the highest degree of emphysema (P < 0.001). Emphysema severity score was also associated with long-term survival (log-rank P = 0.03).
CONCLUSIONS: The regional severity of emphysema assessed via a visual scale using CT appears to be associated with the location of lung cancer and is an independent predictor of long-term survival.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Emphysema; Lung cancer; Screening

Mesh:

Year:  2013        PMID: 23810745     DOI: 10.1016/j.jss.2013.05.081

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  7 in total

1.  Regional Emphysema of a Non-Small Cell Tumor Is Associated with Larger Tumors and Decreased Survival Rates.

Authors:  C Matthew Kinsey; Raúl San José Estépar; Yongyue Wei; George R Washko; David C Christiani
Journal:  Ann Am Thorac Soc       Date:  2015-08

2.  Comparison Between Radiological Semantic Features and Lung-RADS in Predicting Malignancy of Screen-Detected Lung Nodules in the National Lung Screening Trial.

Authors:  Qian Li; Yoganand Balagurunathan; Ying Liu; Jin Qi; Matthew B Schabath; Zhaoxiang Ye; Robert J Gillies
Journal:  Clin Lung Cancer       Date:  2017-10-13       Impact factor: 4.785

3.  Regional Emphysema Score Predicting Overall Survival, Quality of Life, and Pulmonary Function Recovery in Early-Stage Lung Cancer Patients.

Authors:  Jie Dai; Ming Liu; Stephen J Swensen; Shawn M Stoddard; Jason A Wampfler; Andrew H Limper; Gening Jiang; Ping Yang
Journal:  J Thorac Oncol       Date:  2017-01-23       Impact factor: 15.609

Review 4.  Lung cancer screening in patients with chronic obstructive pulmonary disease.

Authors:  Jessica Gonzalez; Marta Marín; Pablo Sánchez-Salcedo; Javier J Zulueta
Journal:  Ann Transl Med       Date:  2016-04

5.  Severity of pulmonary emphysema and lung cancer: analysis using quantitative lobar emphysema scoring.

Authors:  Kyungsoo Bae; Kyung Nyeo Jeon; Seung Jun Lee; Ho Cheol Kim; Ji Young Ha; Sung Eun Park; Hye Jin Baek; Bo Hwa Choi; Soo Buem Cho; Jin Il Moon
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

6.  COPD is commonly underdiagnosed in patients with lung cancer: results from the RECOIL study (retrospective study of COPD infradiagnosis in lung cancer).

Authors:  Dámaso Parrón Collar; Mario Pazos Guerra; Paula Rodriguez; Carolina Gotera; Ignacio Mahíllo-Fernández; Germán Peces-Barba; Luis M Seijo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-03-30

7.  Electronic Medical Record Inaccuracies: Multicenter Analysis of Challenges with Modified Lung Cancer Screening Criteria.

Authors:  Candice L Wilshire; Carson C Fuller; Christopher R Gilbert; John R Handy; Kimberly E Costas; Brian E Louie; Ralph W Aye; Alexander S Farivar; Eric Vallières; Jed A Gorden
Journal:  Can Respir J       Date:  2020-03-26       Impact factor: 2.409

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.